Nirmalanandhan Victor Sanjit, Sittampalam G Sitta
University of Kansas Medical Center & Kansas Masonic Cancer Research Center, Department of Pharmacology Toxicology and Therapeutics, The Institute for Advancing Medical Innovation, Kansas City, Kansas 66160, USA.
J Biomol Screen. 2009 Aug;14(7):755-68. doi: 10.1177/1087057109336591. Epub 2009 Aug 12.
Stem cells, irrespective of their origin, have emerged as valuable reagents or tools in human health in the past 2 decades. Initially, a research tool to study fundamental aspects of developmental biology is now the central focus of generating transgenic animals, drug discovery, and regenerative medicine to address degenerative diseases of multiple organ systems. This is because stem cells are pluripotent or multipotent cells that can recapitulate developmental paths to repair damaged tissues. However, it is becoming clear that stem cell therapy alone may not be adequate to reverse tissue and organ damage in degenerative diseases. Existing small-molecule drugs and biologicals may be needed as "molecular adjuvants" or enhancers of stem cells administered in therapy or adult stem cells in the diseased tissues. Hence, a combination of stem cell-based, high-throughput screening and 3D tissue engineering approaches is necessary to advance the next wave of tools in preclinical drug discovery. In this review, the authors have attempted to provide a basic account of various stem cells types, as well as their biology and signaling, in the context of research in regenerative medicine. An attempt is made to link stem cells as reagents, pharmacology, and tissue engineering as converging fields of research for the next decade.
在过去20年中,无论起源如何,干细胞已成为人类健康领域有价值的试剂或工具。最初,作为研究发育生物学基本方面的一种研究工具,如今干细胞已成为生成转基因动物、药物发现以及用于治疗多器官系统退行性疾病的再生医学的核心焦点。这是因为干细胞是多能或多潜能细胞,能够重现发育路径以修复受损组织。然而,越来越明显的是,仅靠干细胞疗法可能不足以逆转退行性疾病中的组织和器官损伤。在治疗中给予的干细胞或患病组织中的成体干细胞可能需要现有的小分子药物和生物制剂作为“分子佐剂”或增强剂。因此,基于干细胞的高通量筛选和3D组织工程方法相结合对于推动临床前药物发现的下一波工具发展是必要的。在这篇综述中,作者试图在再生医学研究的背景下,对各种干细胞类型及其生物学和信号传导提供一个基本概述。试图将干细胞作为试剂、药理学和组织工程联系起来,作为未来十年研究的融合领域。